Antibodies recognizing tau

Patent metadata

Field	Value
Publication number	US-11584791-B2
Application number	US-202017089416-A
Country	US
Kind code	B2
Filing date	Nov 4, 2020
Priority date	May 2, 2016
Publication date	Feb 21, 2023
Grant date	Feb 21, 2023

Abstract

The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

First claim

What is claimed is:

1. A nucleic acid encoding a mature heavy chain variable region fused to a heavy chain constant region, wherein the mature heavy chain variable region has an amino acid sequence comprising any one of SEQ ID NOS:15-19 and SEQ ID NOS:46-57.

2. The nucleic acid of claim 1 , wherein the mature heavy chain variable region has an amino acid sequence comprising SEQ ID NO:15.

3. A recombinant expression vector comprising the nucleic acid of claim 2 .

4. A host cell transformed with the recombinant expression vector of claim 3 .

5. The nucleic acid of claim 1 , wherein the heavy chain constant region is a mutant form of a natural human heavy chain constant region which has reduced binding to a Fcγ receptor relative to the natural human heavy chain constant region.

6. The nucleic acid of claim 1 , wherein the heavy chain constant region is of IgG1 isotype.

7. The nucleic acid of claim 1 , wherein the heavy chain constant region has at least one mutation.

8. The nucleic acid of claim 7 , wherein the mutation reduces complement fixation or activation by the constant region.

9. The nucleic acid of claim 8 , having a mutation at one or more of positions 241, 264, 265, 270, 296, 297, 318, 320, 322, 329 and 331 by EU numbering.

10. The nucleic acid of claim 9 , wherein the heavy chain constant region has alanine at positions 318, 320 and 322.

11. The nucleic acid of claim 1 , wherein the isotype of the constant region is human IgG2 or IgG4 isotype.

12. A recombinant expression vector comprising the nucleic acid of claim 1 .

13. A host cell transformed with the recombinant expression vector of claim 12 .

14. A nucleic acid encoding a mature light chain variable region, wherein the mature light chain variable region has an amino acid sequence comprising any one of SEQ ID NOS:_21-23.

15. A recombinant expression vector comprising the nucleic acid of claim 14 .

16. A host cell transformed with the recombinant expression vector of claim 15 .

17. A method of humanizing a mouse antibody, the method comprising:
(a) selecting human acceptor antibody sequences;
(b) identifying CDRs and variable region framework amino acid residues of the mouse antibody to be retained;
(c) determining amino acid sequences of a humanized heavy chain variable region and a humanized light chain variable region from the CDRs and variable region framework amino acid residues of the mouse antibody to be retained and the one or more human acceptor antibody sequences;
(c) synthesizing a nucleic acid encoding the humanized heavy chain and a nucleic acid encoding the humanized light chain; and
(d) expressing the nucleic acids in a host cell to produce a humanized antibody;
wherein the mouse antibody is characterized by a mature heavy chain variable region of SEQ ID NO:7 and a mature light chain variable region of SEQ ID NO:11.

Assignees

• Prothena Biosciences Ltd

Inventors

• Barbour Robin
• Dolan Iii Philip James
• Liu Yue
• Alexander Svetlana
• Renz Mark E

Classifications

• G01N2800/2821

  Alzheimer · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• G01N2333/4709

  Amyloid plaque core protein · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• C07K16/18 Primary

  against material from animals or humans · CPC title